194 participants
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2024-08-01
- Start Date:
- 2021-05-14
- Completion:
- 2024-05-24
Conditions
- TNBC - Triple-Negative Breast Cancer
- Breast Cancer
Interventions
- DRUG
No Results Yet